Publications by authors named "Nisha De Silva"
Article Synopsis
- Complex karyotypes (CKTs) and highly complex karyotypes (hCKTs) are significant predictors of worse outcomes in chronic lymphocytic leukemia (CLL) when treated with chemoimmunotherapy, and their impact is further explored in venetoclax-based therapies.
- * In a study involving 895 patients, CKTs were linked to shorter progression-free survival (PFS) and overall survival (OS) in the CIT group, while hCKTs negatively affected PFS in the venetoclax group.
- * The findings suggest that karyotype analysis should be included in standard CLL diagnostics to better identify patients at high risk for poor treatment outcomes, supporting more personalized treatment approaches.
Article Synopsis
- The study investigates the effectiveness of venetoclax combined with anti-CD20 antibodies in fit patients with advanced chronic lymphocytic leukemia (CLL), compared to traditional chemoimmunotherapy.
- In a phase 3 trial with 926 participants, various treatment regimens were compared, emphasizing the primary goals of achieving undetectable minimal residual disease and prolonging progression-free survival.
- Results showed that venetoclax combinations significantly outperformed chemoimmunotherapy in terms of undetectable minimal residual disease rates and 3-year progression-free survival, especially in the venetoclax-obinutuzumab-ibrutinib group.
Fludarabine, cyclophosphamide and rituximab (FCR) was compared to bendamustine and rituximab (BR) in an international, randomized, open label, phase 3 trial in 561 previously untreated, fit patients with chronic lymphocytic leukemia (CLL) without del (17p). Primary endpoint was progression free survival (PFS). The final primary endpoint analysis after 37.
View Article and Find Full Text PDFThe introduction of chemoimmunotherapy and more recently the implementation of novel agents into first-line and relapse treatment have substantially improved treatment outcomes in patients with chronic lymphocytic leukaemia (CLL). With longer progression-free survival and more frequently observed deep remissions there is an emerging need for sensitive methods quantitating residual disease after therapy. Over the last decade, assessment of minimal residual disease (MRD) has increasingly been implemented in CLL trials.
View Article and Find Full Text PDF